Skip to content

Lauren N Vale

3 papers in the library · 7 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study.

BMJ Open July 13, 2026 Thomas D Meyer, Lauren N Vale, Maya Ibrahim et al.

Bipolar II disorder (BD-II) is characterised by hypomanic and depressive episodes with the latter tending to dominate the clinical course of the disorder, and they are often associated with suicidality. Despite available guideline-based recommendations for first-line pharmacological treatments, patient outcomes remain suboptimal, especially for those with chronic depression and suicidal...

Contemplating versus having used psychedelics in bipolar disorder - What makes the difference?

Journal of Affective Disorders February 1, 2026 Lauren N Vale, Maya Ibrahim, Leonardo Fávaro-pereira et al. 1 citation

In recent years psychedelics have gained popularity and potential promise in the field of mental health, but for patients diagnosed with bipolar disorder (BD), fears of emerging manic or psychotic symptoms have caused investigators to exclude them from psychedelic research. In this observational study, we explore the motivations, expectations, and personality characteristics of individuals with...

Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.

Journal of Affective Disorders March 15, 2025 Thomas D Meyer, Maya Ibrahim, Lauren N Vale et al. 6 citations

Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other mental health problems. However, individuals with bipolar disorder (BD) have been excluded from most clinical trials due to concerns about manic switches or psychosis. This study aimed to systematically examine the effects of recreational psychedelic...